Sign in

Trial result ·

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This study tested upadacitinib, a daily pill, in people with vitiligo. In vitiligo, the skin loses its color. The people had the non-segmental type on the face and body. They were adults and teens aged 12 years or more. The work joined phase 3 trials at 138 sites in 18 countries. People were put into groups by chance. Some took upadacitinib 15 mg once a day. The others took a dummy pill. Neither the people nor the doctors knew who took which. The return of skin color was checked at week 48.

What they found

In the first trial, 206 people took the drug. In that trial, 102 people took the dummy pill. In the second trial, 205 took the drug and 101 took the dummy pill. At week 48, more people on the drug had regained skin color. This was true for the whole body and for the face. For the body goal, 40 and 44 people on the drug got there. Fewer people on the dummy pill did so. No major heart events or blood clots were reported. There was no lymphoma, active TB, or non-melanoma skin cancer. Safety was in line with what is known for this drug.

What it means for patients

The authors say the drug brought back skin color in a way that mattered. This was seen on both the face and the whole body. It held for adults and teens with this type of vitiligo. The team found no new safety concerns. The abstract notes that no whole-body drug is yet approved for this disease.

Why it is not certain yet

The results cover only 48 weeks of treatment. The study is still going on. So results from longer use are not yet known. The abstract does not say how often side effects happened. The drug maker, AbbVie, paid for the study.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

PubMed · PMID 42594914

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Vitiligo publications